10-Q: United Health Products Reports Q3 2024 Results, Focus Remains on FDA Approval

United Health Products reports a net loss for Q3 2024, with no revenue, as the company continues to focus on obtaining FDA approval for its CelluSTAT product.

Summary

• United Health Products reported a net loss of $303,662 for the three months ended September 30, 2024, compared to a net loss of $485,732 for the same period in 2023.
• The company did not generate any revenue in either period, as it is focused on obtaining FDA Class III pre-market approval (PMA) for its CelluSTAT hemostatic gauze.
• Operating expenses decreased to $391,903 in Q3 2024 from $450,451 in Q3 2023, primarily due to lower research and development costs.
• The company recorded a gain of $115,085 on the settlement of debt, which positively impacted other income (expense).
• For the nine months ended September 30, 2024, the net loss was $1,187,621, compared to a net loss of $2,151,349 for the same period in 2023.
• Operating expenses for the nine-month period decreased to $1,222,174 from $1,979,882 in the prior year, due to lower litigation settlement, legal, professional, and research and development expenses.
• The company's cash and cash equivalents were $43,783 as of September 30, 2024, down from $95,420 at the end of 2023.
• The company has a negative working capital of $2,171,720 as of September 30, 2024.
• The company is relying on the sale of equity securities and other financing sources to fund its operations.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the lack of revenue, negative working capital, and the delay in FDA approval. However, the company is actively addressing the FDA's concerns and has reduced its net loss compared to the previous year.

Positives

• The net loss decreased in both the three and nine-month periods compared to the previous year.
• Operating expenses decreased in both the three and nine-month periods compared to the previous year.
• The company recorded a gain on settlement of debt.
• The company is actively working with the FDA to address deficiencies in its PMA application.
• The company has proposed a multi-site study to address FDA concerns about the safety and effectiveness of CelluSTAT in surgical procedures.

Negatives

• The company has not generated any revenue in the current or prior year.
• The company has a negative working capital of $2,171,720.
• The company's cash and cash equivalents have decreased significantly.
• The company is reliant on external financing to continue operations.
• The FDA has issued a 'Deficiencies Letter' regarding the PMA application, pausing the review period.
• There is no assurance that the company will receive FDA approval for its Class III PMA application.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• The company is reliant on receiving Premarket Approval (PMA) from the FDA for its CelluSTAT product.
• The FDA may not approve the company's Class III PMA application.
• The company is subject to extensive regulation by the FDA and must comply with these regulations.
• The company may not be able to expand into international markets if it does not receive regulatory clearances.
• The company is evaluating potential commercial partnerships but there is no assurance that any will be entered into.

Future Outlook

The company is focused on obtaining FDA pre-market approval for its CelluSTAT product and is evaluating paths to grow revenue and profits, including potential sale or merger, or commercial partnerships. The company is also planning a multi-site study to address FDA concerns.

Management Comments

• Management believes there is an opportunity for CelluSTAT products to address unmet needs in several medical applications.
• Management believes that the CelluSTAT technology could successfully compete against established Class III market participants.
• Management does not intend to pursue the full commercialization of its products independently nor to remain an independent company in the long term.

Industry Context

The company is operating in the hemostatic gauze market, which is competitive, particularly in the Class III surgical space. The company is seeking to differentiate itself through its patented technology and the absence of chemical additives, thrombin, collagen, or animal-derived products in its CelluSTAT product.

Comparison to Industry Standards

• The company's lack of revenue is not unusual for a pre-commercial stage medical device company focused on regulatory approval.
• The company's operating expenses are typical for a company in its stage of development, with significant costs associated with research and development and regulatory submissions.
• The company's reliance on external financing is common for companies in the medical device sector that have not yet achieved commercialization.
• The company's negative working capital is a concern and highlights the need for additional funding.
• The company's focus on obtaining Class III PMA is a strategic move to target a higher-value market segment, similar to other companies in the hemostatic device space such as Baxter and Ethicon, who have established products in the surgical market.

Related Party Transactions

• The company has convertible notes payable to related parties, including the CEO and a director.
• The company has accrued liabilities to related parties, including officers and management.

Stakeholder Impact

• Shareholders are impacted by the company's continued losses and reliance on equity financing.
• Employees are impacted by the company's financial situation and the uncertainty surrounding FDA approval.
• Customers are impacted by the delay in the availability of the company's CelluSTAT product in the surgical market.
• Suppliers are impacted by the company's financial situation and its ability to pay for goods and services.
• Creditors are impacted by the company's negative working capital and its reliance on external financing.

Next Steps

• The company will respond to the FDA's 'Deficiencies Letter'.
• The company will conduct a multi-site study to address FDA concerns about the safety and effectiveness of CelluSTAT in surgical procedures.
• The company will continue to evaluate potential commercial partnerships.
• The company will seek additional financing to fund its operations.

Key Dates

Keywords

FDA, PMA, CelluSTAT, hemostatic gauze, Class III, regulatory approval, clinical trial, medical device, surgical market, wound care